Key results of the pivotal tazemetostat study30
| Patient cohort . | Number of patients . | ORR (by IRC) . | CRR . | PFS, median (mo) . | DOR, median (mo) . | Treatment-related adverse events (any grade) in ≥10% of patients . | Treatment-related adverse events (grade 3-4) in ≥2% of patients . |
|---|---|---|---|---|---|---|---|
| EZH2 mutated | 45 | 69% | 13% | 14 | 11 | Nausea (19%) | Anemia (2%) |
| EZH2 wild-type | 54 | 35% | 4% | 11 | 13 |
|
|
| Patient cohort . | Number of patients . | ORR (by IRC) . | CRR . | PFS, median (mo) . | DOR, median (mo) . | Treatment-related adverse events (any grade) in ≥10% of patients . | Treatment-related adverse events (grade 3-4) in ≥2% of patients . |
|---|---|---|---|---|---|---|---|
| EZH2 mutated | 45 | 69% | 13% | 14 | 11 | Nausea (19%) | Anemia (2%) |
| EZH2 wild-type | 54 | 35% | 4% | 11 | 13 |
|
|
CRR, complete response rate; DOR, duration of response; IRC, independent review committee; ORR, overall response rate.